Sydney Jennings

MR-100A-01 weekly contraceptive patch data will be presented ahead of an FDA decision on the investigational lower-estrogen product.

South London data show stroke rates climbing again, hitting Black communities and poorer areas hardest, and exposing gaps in prevention and follow-up.

Highlights include clinical gaps in menopause care, postpartum prevention, cervical cancer screening, pregnancy-related infection, and GLP-1 RA exposure.

Bariatric surgery was associated with lower 2-year costs than GLP-1 therapy in adults with obesity and type 2 diabetes, according to new real-world data.

DDW 2026 data show real-world, 52-week IBD outcomes with risankizumab and upadacitinib, including persistence, fewer switches, and hospital visits.

DDW 2026: Four-year LUCENT-3 data show mirikizumab maintains composite disease clearance in over 60% of UC patients, marking a first for IL-23p19 inhibitors.

FDA updates include oral GLP-1 therapy, HIV regimen, gene therapy for hearing loss, and diabetes technology advances.

Network meta-analysis suggests lumateperone add-on therapy improves MDD symptoms most, with minimal weight gain and placebo-like akathisia risk.

Late-breaking data presented at ACOG 2026 showed GLP-1 RA exposure before or during early pregnancy was not associated with hypertensive disorders of pregnancy.

A nationally representative study found 71.5% of US women aged 21-49 years were open to HPV self-collection, including 9.7 million who were underscreened or never screened.

Hear from the presenting investigator of late-breaking research presented at ACOG 2026 that found over 80% of pregnancy-related infection deaths were preventable.

ACOG 2026: In a nationally representative survey, 75% of women with menopausal symptoms reported sleep problems vs 49.8% without symptoms.

New research shows 35.3% of insured individuals with hypertensive disorders of pregnancy had a preventive care visit within 12 months postpartum.

ECHO-based menopause education improved PCP confidence and revealed gaps in sexual health, bleeding, and weight management training, according to new research.

Details on 11 key abstracts with clinical relevance for primary care, from menopause management to cervical cancer screening.

ACP Internal Medicine Meeting 2026 highlights: new mammography guidelines, AI scribe limitations, and muscle loss risks with GLP-1 weight loss drugs.

WHO’s 2025 kidney health resolution pushes nations to spot CKD earlier, bolster primary care treatment, and expand dialysis and transplant access.

Phase 3 data show IL‑33 antibody tozorakimab cuts COPD flare-ups across smokers and low eosinophils, hinting a new biologic option.

The TRIDENT trial shows a once-daily triple BP pill after intracerebral hemorrhage improves control and lowers recurrent stroke and cardiovascular events.

FDA approves doravirine/islatravir for adults with virologically suppressed HIV-1, offering a once-daily 2-drug regimen with noninferior efficacy.

Steven Nissen, MD, discusses new SURPASS-CVOT data showing reduced cardiorenal events and mortality with tirzepatide vs dulaglutide.

A new executive order aims to speed up FDA access to psychedelic therapies; psychiatrist Gus Alva, MD, reviews evidence, safety risks, and more.

Test your knowledge of 2024 CDC STI data on high-risk populations and what it means for your screening decisions.

Test your knowledge of 2024 syphilis trends, staging distribution, and declines in primary and secondary disease.

Phase 3 CORALreef AddOn shows oral PCSK9 inhibitor enlicitide cuts LDL 65% on statins, potentially easing primary care lipid control.

Highlights include once-weekly insulin, obesity therapies, and new options for psoriasis and rare diseases.

Try your hand at these 5 questions on the latest US CDC STI data.

Women with diabetes receive less contraception, cancer screening, and preconception care, increasing risk for preventable complications.

Study of 669 083 patients links antidepressants and some antidiarrheals to higher mortality in IBS, raising prescribing concerns.

Phase 3 data show an investigational 6-valent OspA-based Lyme vaccine prevents more than 70% of cases; regulatory submissions planned.